Welcome to our dedicated page for Solventum SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Solventum's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Solventum's regulatory disclosures and financial reporting.
Knight Heather reported acquisition or exercise transactions in this Form 4 filing.
Solventum Corp reported that Chief Commercial Officer Heather Knight received a grant of 31,789 Restricted Stock Units (RSUs) on March 5, 2026. Each RSU represents a contingent right to receive one share of Solventum’s Class A common stock upon settlement.
The RSUs vest in three equal tranches, with one-third vesting on each of the first, second, and third anniversaries of the grant date, conditioned on Ms. Knight’s continued service through each vesting date. Following this grant, she directly holds 31,789 RSUs.
Solventum Corp’s Chief Legal Affairs Officer, Marcela A. Kirberger, reported several equity-related transactions in company stock. She received a grant of 14,835 Restricted Stock Units (RSUs), each representing one share of Class A Common Stock upon settlement, vesting in three equal annual installments.
On a separate date, she exercised 4,180 RSUs, converting them into the same number of Common Stock shares at a stated price of $0.00 per share, and 1,232 Common Stock shares were disposed of at $69.41 per share to cover tax obligations. Following these transactions, she directly held 11,004 Common Stock shares and 8,363 RSUs.
Solventum Corporation filed its Annual Report on Form 10-K describing its global healthcare operations, spin-off risks and capital structure.
The company reports an aggregate market value of common stock held by non‑affiliates of about $13.1 billion as of its most recent second fiscal quarter and 173,493,005 shares outstanding as of February 18, 2026. Its 2025 sales were led by MedSurg at 57.9%, with Dental Solutions at 16.2% and Health Information Systems at 16.3%.
Solventum highlights its separation from 3M, noting potential challenges in systems, capital access and the loss of 3M scale benefits. As of December 31, 2025, it carried approximately $5 billion of outstanding debt. The report also notes the 2025 acquisition of Acera Surgical and the sale of its Purification and Filtration business to Thermo Fischer Scientific Inc., along with extensive regulatory, environmental, data privacy and healthcare policy risks.
Solventum Corporation reported fourth-quarter 2025 sales of $1.998 billion, down 3.7% on a reported basis but up 3.5% organically, showing underlying growth despite divestitures. GAAP diluted EPS rose to $0.36, while adjusted diluted EPS increased to $1.57.
For full-year 2025, sales reached $8.325 billion, up 0.9% with 3.3% organic growth. GAAP diluted EPS jumped to $8.88, largely reflecting a $1.549 billion gain on a business sale, while adjusted diluted EPS declined to $6.11 from $6.70. Operating cash flow fell to $369 million and free cash flow was slightly negative at $10 million. Long-term debt decreased to $5.035 billion from $7.810 billion. For 2026, Solventum guides to 2.0%–3.0% organic sales growth (3.0%–4.0% excluding SKU exits), adjusted EPS of $6.40–$6.60, and free cash flow of about $200 million.
Solventum Corp’s Chief Information Officer, Amy Landucci, reported equity compensation activity involving restricted stock units and common shares. On February 1, 2026, she converted 26,921 fully vested restricted stock units into the same number of Solventum common shares. Each RSU represented the right to receive one share upon settlement.
On the same date, 10,453 common shares were withheld in a transaction coded "F" at a price of $76.97 per share, typically indicating tax withholding associated with the vesting event. After these transactions, she directly owned 35,419 shares of Solventum common stock.
Independent Franchise Partners, LLP filed an amended Schedule 13G reporting its beneficial ownership of common stock of CORPORATION. The firm reports beneficial ownership of 15,355,691 shares, representing 8.85% of the outstanding common stock as of the event date. It has sole voting power over 15,002,913 shares and shared voting power over 91,652 shares. It also has sole dispositive power over all 15,355,691 shares and no shared dispositive power. The filer states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Solventum Corp reported an insider equity transaction by its Chief Human Resources Officer, Tammy L. Gomez. On 01/02/2026, she acquired 4,342 shares of Solventum common stock through the settlement of restricted stock units. On the same date, 1,332 shares were disposed of at $79.2 per share, typically reflecting shares withheld to cover taxes.
After these transactions, Gomez directly beneficially owned 8,665 shares of Solventum common stock. The filing explains that each RSU converts into one share of common stock upon settlement, and that the RSUs vest in three equal annual tranches on the first, second, and third anniversaries of the grant date, subject to continued service.
Solventum Corporation furnished a letter to its shareholders under a Regulation FD disclosure.
On December 16, 2025, the company issued a shareholder letter and attached it as Exhibit 99.1 to a current report. The company states that this information is being furnished, not filed, so it is not subject to liability under Section 18 of the Exchange Act and will only be incorporated into other securities filings if specifically referenced. Solventum’s common stock, with a par value of $0.01 per share, trades on the New York Stock Exchange under the symbol SOLV.
Solventum Corp’s Chief Legal Affairs Officer reported routine equity transactions in company stock. On 12/01/2025, the officer exercised 3,811 restricted stock units, receiving the same number of Solventum common shares as they fully vested. To cover tax obligations, 1,510 shares were disposed of at a price of $85.56 per share. After these transactions, the officer directly owned 8,056 shares of Solventum common stock. These transactions were reported on a Form 4 as a single‑person filing.
Solventum Corp reported an insider equity transaction by its Chief Supply Chain Officer, who filed individually. On 12/01/2025, 10,463 shares of common stock were acquired through the settlement of fully vested restricted stock units, reflected as a Code M transaction. On the same date, 4,528 shares of common stock were disposed of in a Code F transaction at $85.56 per share, typically indicating shares withheld to cover taxes.
After these transactions, the officer beneficially owned 15,943 shares of Solventum common stock in direct ownership. All related restricted stock units were fully vested, and each RSU represented the right to receive one share of common stock upon settlement.